MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Objective measurement of limb bradykinesia using marker-less tracking algorithm with 2D-video of PD patients

    J.H Shin, S.H Jeon, R. Kim, S.M Park, J.H Choi, J.N Ong, H.J Kim, B. Jeon (Seoul, Republic of Korea)

    Objective: To objectively analyze motor symptoms with 2D RGB videos, which are easily accessible, attachment free and cost-effective. Background: Quantitative measurement of parkinsonian symptoms is…
  • MDS Virtual Congress 2020

    Arm Swing Differences in Patients with PD and ET during Walking

    W.S Zhang, C. Gao, P.C Zhang, G. Li, S.D Chen (Shanghai, China)

    Objective: To identify objective biomarkers to improve clinical phenotyping and differential diagnosis in patients with PD and ET using wearable sensors. Background: At present, the…
  • MDS Virtual Congress 2020

    Positional variability in upper limb tremor in both essential and dystonic tremor: A case series

    J. Anang (Winnipeg, MB, Canada)

    Objective: Characterize the positionality of upper limb tremor in clinical practice. Background: The MDS tasks force on tremor defines tremor as an involuntary, rhythmic, oscillatory…
  • MDS Virtual Congress 2020

    Quantitative study of the effect of thalamotomy by MRgFUS in the different types and locations of tremor in the contralateral upper limb

    P. Manrique-de-Lara, J.A Martin, I. Aviles, A. Gorospe, J. Guridi, L. Gonzalez, M. Alegre, G. Besne, M.C Rodriguez-Oroz (Pamplona, Spain)

    Objective: To quantify the improvement of different types of tremor in upper limb using the spectrum of accelerometer signal in patients treated with unilateral lesions…
  • MDS Virtual Congress 2020

    Use of Botulinum Toxin: Experience in a Cohort of Essential Tremor Patients

    C. Shah, F. Jamal, A. Sarwar, G. Jackson (Houston, TX, USA)

    Objective: To review the treatment characteristics of botulinum toxin in medically refractory essential tremor (ET). Background: Treatment of medically refractory essential tremor has remained challenging…
  • MDS Virtual Congress 2020

    Feasibility and Acceptability of Lee Silverman Voice Treatment for patients with hereditary ataxia

    A.N. Lowit, A. Egan, M. Hadjivassiliou (Glasgow, United Kingdom)

    Objective: This study aimed to assess the feasibility and acceptability of Lee Silverman Voice Treatment (LSVT) provided via Skype for patients with hereditary ataxia. Background:…
  • MDS Virtual Congress 2020

    New pathogenic mutation in the Niemann-Pick C (NPC) Type 1 gene: Confirmation by diagnostic workup of NPC in a 41-year-old woman with idiopathic late onset cerebellar ataxia (ILOCA)

    G. Crotty, J.Y Chen, D. Brockman, J. Schmahmann (Boston, MA, USA)

    Objective: We present an instructive case of a 41-year-old woman with idiopathic late onset cerebellar ataxia. Background: Identifying the cause of idiopathic late onset cerebellar…
  • MDS Virtual Congress 2020

    Downbeat nystagmus and progressive ataxia mimicking a neurodegenerative disease: a specific phenotype of Chiari malformation

    B. Massuyama, F. Filho, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

    Objective: Case Report. Background: Chiari malformation type 1 (CM1) is a congenital neurological disease with posterior fossa hypoplasia and the cerebellar tonsils being forced through…
  • MDS Virtual Congress 2020

    Gerstmann-Sträussler-Scheinker disease presenting as a late onset slowly progressive spinocerebellar ataxia: expanding the phenotypic spectrum of genetic prion disease

    C. Stephen, J. Chen, B. Appleby, T. Prior, M. Frosch, J. Schmahmann (Boston, MA, USA)

    Objective: We describe a late-onset presentation of Gerstmann-Sträussler-Scheinker disease (GSS) with a novel mutation in the prion protein (PRNP) gene. We compare this case to…
  • MDS Virtual Congress 2020

    The Impact of Antipsychotic Dose Reduction Within a Medicare Population

    R. Ayyagari, F. Mu, A. Lax, B. Carroll (Boston, MA, USA)

    Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 149
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley